Trehalose ophthalmic solution,
does it really help with Improvement of dry-eye symptoms and tear-film stability?
research showsTrehalose-containing eye drops are rated C because they may modestly improve dry-eye symptoms and corneal staining. Across 10 trials and 1,252 participants, OSDI changed by -8.5 points, tear-film breakup time by +1.9 seconds, and corneal staining by -0.7, while the Schirmer effect was only +0.8 mm. Nine or ten trials concentrated on the Thealoz Duo brand, formulation heterogeneity was substantial, and outcomes remained symptoms, staining, and tear-film surrogates. Long-term improvement in ocular-surface disease course has not been established.
ads claimMarketing can expand cytoprotection into claims that the drops fundamentally rebuild the tear film or treat the cornea for the long term. Human evidence mainly supports relief of symptoms and ocular-surface staining over weeks to months as an artificial tear; a cellular mechanism is not proof of long-term disease modification.
Useful facts when choosing a product
- Trehalose ophthalmic solutions are artificial tears designed to wet the ocular surface and protect cells from osmotic and desiccation stress.
- Trials include both trehalose-only solutions and formulations combining 3% trehalose with 0.15% hyaluronic acid, so results from one formulation cannot automatically be applied to every product.
- Even with a preservative-free multidose bottle, the tip should not touch the eye or lashes, and persistent pain, marked redness, or reduced vision warrants stopping use and obtaining clinical assessment.
- The product label governs contact-lens compatibility and spacing from other eye medicines, and prescribed ophthalmic treatment should not be replaced with a trehalose artificial tear.
What the research actually shows
Ballesteros-Sánchez and colleagues in 2023 reviewed 10 full-length randomized trials covering OSDI, tear-film breakup time, tear-film thickness, tear-meniscus height, Schirmer testing, and corneal staining. Mean between-group differences generally favored trehalose, but the Schirmer difference was only 0.8±1.4 mm and consistency was limited. Matsuo and colleagues in 2002 randomized 34 patients in a double-masked fellow-eye design for four weeks; staining improved with 100 or 200 mM trehalose versus saline, while tear-film breakup time improved only with 100 mM. Chiambaretta and colleagues in 2017 found hyaluronic acid plus trehalose noninferior to hyaluronic acid alone in 105 patients; some early symptoms favored the combination, but staining improvement at day 84 was similar, and Laboratoires Théa funded the trial.
Why this is classified as C (58)
Ten trials and 1,252 participants support OSDI, tear-film breakup time, and corneal-staining surrogates, while Schirmer improved by only +0.8 mm. Most trials focused on Thealoz Duo, mixed formulations and comparator designs, and did not measure long-term disease outcomes. The surrogate-outcome and brand-concentration rules cap efficacy at C with 58 points, while transient ocular irritation remains a separate safety caution.
Counterpoint. For patients whose dry-eye symptoms are not adequately relieved by a basic lubricant, a trehalose-hyaluronic acid formulation can be a reasonable symptomatic option. Pain, photophobia, reduced vision, or severe unilateral redness should not be self-treated as simple dry eye.
Rejudgment record. Reassessment (cross-check reflected) — Accepted positive symptom, corneal-staining, and tear-film surrogates while applying the C ceiling under rules ① and ②-b because of Thealoz Duo brand concentration, formulation heterogeneity, minimal Schirmer change, and absent long-term disease outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of dry-eye symptoms and corneal staining | C | Surrogate outcomes are positive, but the evidence is dominated by brand-specific trials. |
| Objective tear-film measures including tear volume | C | Changes in Schirmer and related measures are minimal. |
| Long-term improvement in ocular-surface disease course | ? | No long-term clinical-course trial was identified. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Systematic review of randomized trials of trehalose tear substitutes | 10 | The authors reported no conflicts of interest | OSDI, tear-film breakup time, tear-film thickness, tear-meniscus height, Schirmer testing, and corneal fluorescein staining | Reported mean between-group differences generally favored trehalose, but the Schirmer difference was small and formulations and comparators varied across trials. | Key synthesis with heterogeneity |
| Study 2 | Randomized double-masked dose-ranging fellow-eye-controlled trial | 34 | Inadequately reported in the abstract | Symptoms, fluorescein and rose-bengal staining, and tear-film breakup time | Staining improved versus saline with 100 and 200 mM, while tear-film breakup time increased significantly only with 100 mM. | Direct short-term saline-controlled evidence |
| Study 3 | Multicenter randomized investigator-masked active-controlled phase III trial | 105 | Supported by Laboratoires Théa; some authors received consulting or investigator fees | Day-35 noninferiority in Oxford ocular-surface staining and day-84 symptoms and signs | Hyaluronic acid plus trehalose was noninferior to hyaluronic acid alone and favored some early symptoms, but staining changes were similar at day 84. | Representative product trial with manufacturer concentration |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Trehalose ophthalmic solution x improvement of dry-eye symptoms and tear-film stability — Evidence Grade C·58. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/trehalose-ophthalmic-solution-dry-eye-symptoms-tear-film/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.